KDM1A and small cell lung carcinoma: Similarly, LSD1 inhibitors such as ORY-1001 (preclinical), tested alone or in combination with γ-secretase inhibitors (DBZ and RO4929097) in SCLC patient-derived xenograft models, and GSK2879552 (phase I, NCT02034123) in relapsed/refractory SCLC, highlight the potential of targeting chromatin modifiers to impair dormancy-associated survival programs [160,161].